Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
How retinoic acid makes dopaminergic neuron subtypes more vulnerable in Parkinson's Disease
EF 2021-22
Résumé
Parkinson's Disease (PD) is the second most common neurodegenerative disease characterized by the loss of dopaminergic (DA) neurons in the substantia nigra. It affects roughly 100,000 Canadians and is expected to increase with our ageing population. Even though many neuron populations were affected by PD pathogenesis, it is unclear why DA neurons were the most vulnerable. Among these DA neurons, specific subtypes are more susceptible than the others. Anatomically, neurons of the substantia nigra pars compacta (SNc) are more affected in PD than the adjacent ventral tegmental area (VTA) neurons. SNc neurons that express Aldh1a1 are more vulnerable than those that do not. Aldh1a1 is an aldehyde dehydrogenase, and it is involved in detoxifying by-products of dopamine degradation and synthesizing retinoic acid (RA), a transcription regulator. We believe during axon retraction due to neurodegeneration, Aldh1a1 is brought closer to the nucleus of DA neurons. Since RA usually is not present in the nucleus of DA neurons, the relocation of Aldh1a1 may lead to transcription dysregulations for DA neurons. Furthermore, RA has been found to interact with a-syn, which form pathological aggregates causing PD; therefore, we will study the vulnerability of Aldh1a1+ neurons in a-syn-induced neurodegeneration and the role of RA and the enzyme Aldh1a1 in neuron vulnerability. It is essential to uncover mechanisms that may lead to increased vulnerability of DA neurons. After discovering what causes increased vulnerability, we can design therapeutic targets to slow or prevent PD progression.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
458796
Name
Sung Chin Chia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
How retinoic acid makes dopaminergic neuron subtypes more vulnerable in Parkinson's Disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
A-Synuclein; Aldh1a1; Parkinson'S Disease; Retinoic Acid; Selective Vulnerability
Abstract
Parkinson's Disease (PD) is the second most common neurodegenerative disease characterized by the loss of dopaminergic (DA) neurons in the substantia nigra. It affects roughly 100,000 Canadians and is expected to increase with our ageing population. Even though many neuron populations were affected by PD pathogenesis, it is unclear why DA neurons were the most vulnerable. Among these DA neurons, specific subtypes are more susceptible than the others. Anatomically, neurons of the substantia nigra pars compacta (SNc) are more affected in PD than the adjacent ventral tegmental area (VTA) neurons. SNc neurons that express Aldh1a1 are more vulnerable than those that do not. Aldh1a1 is an aldehyde dehydrogenase, and it is involved in detoxifying by-products of dopamine degradation and synthesizing retinoic acid (RA), a transcription regulator. We believe during axon retraction due to neurodegeneration, Aldh1a1 is brought closer to the nucleus of DA neurons. Since RA usually is not present in the nucleus of DA neurons, the relocation of Aldh1a1 may lead to transcription dysregulations for DA neurons. Furthermore, RA has been found to interact with a-syn, which form pathological aggregates causing PD; therefore, we will study the vulnerability of Aldh1a1+ neurons in a-syn-induced neurodegeneration and the role of RA and the enzyme Aldh1a1 in neuron vulnerability. It is essential to uncover mechanisms that may lead to increased vulnerability of DA neurons. After discovering what causes increased vulnerability, we can design therapeutic targets to slow or prevent PD progression.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Sung, Chin Chia
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~